An interventional study of Head of bed position of 0-degrees and Head of bed position of 30-degrees or greater in Large Vessel Occlusion, Stroke and Ischemic Stroke, sponsored by Population Health Research Institute. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Population Health Research Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Ischemic Stroke with a site in Canada — 32 open to participants now, 39 under way, 9 of them phase 3. Ischemic Stroke · Canada.
Among the 117 studies in Ischemic Stroke with a site in Canada, this one is the 11th largest by planned enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2026, is one of 40 with no phase, reaches primary completion later than 28 of the 38 other live ones, and was the 111th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 117 studies in Ischemic Stroke with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 75+
University of Calgary · Sites in Canada, Australia
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States
Ages 18+
Javelin Medical · Sites in Canada, United States, Brazil and 1 more country
Ages 18+
Penumbra Inc. · Sites in Canada, Australia, France and 2 more countries
Ages 18–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 26 · Phase 4 7
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,240 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 275 across the 90 interventional studies, 275 across the 24 observational. Of the 71 that completed or were terminated, 25 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 117 have an industry lead sponsor. The 10 most frequent:
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Population Health Research Institute has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
9 of the studies in Ischemic Stroke with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06403267NoNO Inc.NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy | 2026-12 |
| NCT05724823University of British ColumbiaVirtual Physical Activity Seated Exercise - Phase 2 | 2026-12-31 |
| NCT06027788Icahn School of Medicine at Mount SinaiCTSN Embolic Protection Trial | 2027-04-01 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 117 studies in Ischemic Stroke with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endovascular thrombectomy (EVT), also known as clot retrieval, is a procedure that improves recovery for people who suffer a stroke by removing blood clots from large blood vessels in the brain. However, half of the patients undergoing EVT to remove the clot from a brain vessel still face lasting disabilities or even die within three months.
The investigators of the HoBIT trial are trying to find out if the position of the head of bed improves recovery in patients who undergo EVT after suffering from a stroke.
The purpose of this study is to establish the benefit of head of bed positioning at 0-degrees compared with 30-degrees or more after EVT for improving functional outcomes in adults that suffer from a stroke.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
This study's planned enrollment of 2,240 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Head of bed position of 0-degrees
Other: Head of bed position of 0-degrees
Head of bed position of 30-degrees or greater
Other: Head of bed position of 30-degrees or greater
Flat position with the HoB at 0° elevation for a continuous 24-hour period. Turning to the side (left or right) is permitted, as long as there is no head elevation.
Also known as: HoB position of 0-degrees
Semi-recumbent position with the HoB to at least 30 degrees for a continuous 24-hour period. Head and torso must remain elevated at 30 degrees or higher, using the hospital bed's positioning system.
Also known as: HoB position of >= 30-degrees, HoB position of greater than or equal to 30-degrees, HoB position of ≥ 30-degrees
Functional disability
Functional disability assessed with the modified Rankin Scale (mRS) score. Scores: 0 - No symptoms 1. \- No significant difficulty despite symptoms; able to carry out all usual duties and activities 2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. \- Moderate disability; requiring some help, but able to walk without assistance 4. \- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. \- Dead
Time frame: 90±14 days from randomization
Absolute difference in NIHSS score
Absolute difference in the National Institutes of Health Stroke Scale (NIHSS) scores Scores: 0 - No stroke symptoms 1-4 - Minor stroke 5-15 - Moderate stroke 16-20 - Moderate to severe stroke 21-42 - Severe stroke
Time frame: Between randomization and 36±12 hours from randomization
Early neurological improvement
Early neurological improvement, defined as an absolute decrease of the National Institutes of Health Stroke Scale (NIHSS) score by 4 points or more Scores: 0 - No stroke symptoms 1-4 - Minor stroke 5-15 - Moderate stroke 16-20 - Moderate to severe stroke 21-42 - Severe stroke
Time frame: 36±12 hours from randomization, compared with randomization
Functional impairment
Functional impairment assessed with the Modified Rankin Score (mRS) Scores: 0 - No symptoms 1. \- No significant difficulty despite symptoms; able to carry out all usual duties and activities 2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. \- Moderate disability; requiring some help, but able to walk without assistance 4. \- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. \- Dead
Time frame: Day 7 from randomization or discharge if happens first
Functional independence
Functional independence defined as Modified Rankin Score (mRS) of 2 or less Scores: 0 - No symptoms 1. \- No significant difficulty despite symptoms; able to carry out all usual duties and activities 2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. \- Moderate disability; requiring some help, but able to walk without assistance 4. \- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. \- Dead
Time frame: Day 7 from randomization or discharge if happens first and 90±14 days from randomization
Quality of life assessment
Quality of life assessed with the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scores range from 1 (full health) to 0 (dead), with negative values indicating states that are "worse than dead".
Time frame: 90±14 days from randomization
Intervention adherence
Adherence to the assigned HoB position for 24 hours from randomization, defined as \>80% of total time spent in the assigned HoB
Time frame: First 24 hours from randomization
Total time spent
Total time spent in the assigned HoB position
Time frame: First 24 hours from randomization
Infarct volume
Infarct volume on the brain imaging (CT/ MRI) performed as part of standard clinical care
Time frame: 24 +/- 12 hours from randomization and 5-7 days from randomization
Started Sep 2026 (actual). Primary completion is estimated for Apr 2029, 31 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 31 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Population Health Research Institute →